Bringing the fundamentals into focus…
Back to Celldex Therapeutics, Inc.
How Celldex Therapeutics, Inc. stacks up
CLDX · against 381 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #279 of 382 · scores higher than 6% of peers
Bars: peers in each 10-point band of the valuation score104 peers with a valuation score of 0–9, including CLDX · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -19.9% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -14.6% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -10.4% vs peer median 0.0%
Metric by metric
Position: dot = CLDX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CLDX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 371 reported | -14.6% | 1.9% | 10% | 30% | |
| EBITDA yieldHigher is better · 379 reported | -19.9% | 4.3% | 4% | 50% | |
| Free cash flow yieldHigher is better · 192 reported | -10.4% | -0.3% | 14% | 20% | |
| Book yieldHigher is better · 371 reported | 30.6% | 32.7% | 47% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around CLDX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 279 | 2.7B USD | 8 | 50 | |
| 279 | 1.7B USD | 8 | 30 | |
| 279 | 2.4B USD | 8 | 6 | |
| 279 | 3.4B USD | 8 | 17 | |
| 279 | 2.3B USD | 8 | 25 | |
| 279 | 1.2B USD | 8 | ||
| 279 | 1.4B USD | 8 | ||
| 279 | 3.1B USD | 8 | 27 | |
| 279 | 4.6B USD | 8 | 29 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score